Page 5 - Medical Booth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article PRINCETON, N.J., April 11, 2021 /PRNewswire/  Taiho Oncology, Inc. today announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib (TAS-120) in patients with intrahepatic cholangiocarcinoma (iCCA) harboring  FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy. The data were presented online as an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 Week 1 Clinical Trials Plenary from 2:00 – 3:45 PM ET on April 11, 2021. In the FOENIX-CCA2 trial, 103 patients with locally advanced or metastatic unresectable iCCA harboring  FGFR2 gene rearrangements including fusions who had received one or more prior lines of systemic therapy received futibatinib 20 mg once daily until disease progression or unacceptable toxicity. The study met its primary endpoint of a greater than 20% object

United statesIkuo yamamiyaMartinj birkhoferHiroshi sootomeCraig heitLipika goyalOffice of orphan drug developmentTaiho pharmaceutical co ltdHospital cancer centerDrug administrationTranslational research planning managementTaiho oncology incAmerican association for cancer researchCholangiocarcinoma foundationOtsuka holdings co ltdAmerican cancer society